Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level

A technology of low red blood cells and cleistanone, applied in the field of preparation of cleistanone derivatives, can solve the problems of insufficient hematopoietic raw materials or utilization barriers

Active Publication Date: 2014-11-19
湖北团黄贡茶有限公司
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] (3) Anemia caused by insufficient hematopoietic raw materials or utilization disorders
[0017] 1) Folic acid or B vitamins 12 Anemia caused by deficiency or utilization disorder Megaloblastic anemia caused by absolute or relative deficiency or utilization disorder of folic acid or vitamin B12 due to various physiological or pathological factors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level
  • Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level
  • Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Preparation of Compound Cleistanone

[0039] The preparation method of the compound Cleistanone (I) refers to the literature published by Van Trinh Thi Thanh et al. –4111, August 2011).

[0040]

Embodiment 2

[0041] Example 2 Synthesis of O-Bromoethyl Derivatives (II) of Cleistanone

[0042]Compound I (440 mg, 1.00 mmol) was dissolved in 10 mL of benzene, and tetrabutylammonium bromide (TBAB) (0.04 g), 1,2-dibromoethane (3.760 g, 20.00 mmol) and 6 mL of 50% sodium hydroxide solution. The mixture was stirred at 25 °C for 24 h. After 24 hours, the reaction solution was poured into ice water, extracted twice with dichloromethane immediately, and the organic phase solutions were combined. Then the organic phase solution was washed with water and saturated brine three times successively, then dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1, v / v), and the yellow concentrated elution band was collected to obtain compound II as a yellow solid (344 mg, 63%).

[0043] 1H NMR (500MHz, DMSO-d 6 ...

Embodiment 3

[0047] Example 3 Synthesis of O-(diethylamino)ethyl derivatives (III) of cleistanone Cleistanone

[0048] Compound II (273mg, 0.5mmol) was dissolved in 20mL of acetonitrile, anhydrous potassium carbonate (345mg, 2.5mmol), potassium iodide (84mg, 0.5mmol) and diethylamine (1460mg, 20mmol) were added thereto, and the mixture was heated to reflux for 8h . After the reaction was completed, the reaction solution was poured into ice water, extracted three times with an equal amount of dichloromethane, and the organic phases were combined. The combined organic phases were successively washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1, v / v), and the light yellow concentrated elution band was collected to obtain compound III as a light yellow colloidal solid (16...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of organic synthesis and pharmaceutical chemistry and particularly relates to a Cleistanone derivative, a preparation method thereof and use thereof in the preparation of drugs for resisting anemia caused by low red blood cell level. According to the invention, a novel Cleistanone derivative is synthesized, and a preparation method of the novel Cleistanone derivative is disclosed. Pharmacological experiments indicate that the Cleistanone derivative disclosed by the invention has an effect of resisting anemia caused by low red blood cell level and has a value in the development of the drugs for resisting anemia caused by low red blood cell level.

Description

technical field [0001] The present invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a Cleistanone derivative, a preparation method and an application thereof. Background technique [0002] There are different classifications of anemia based on different clinical features. Such as: acute and chronic anemia according to the progress of anemia; proliferative anemia (such as hemolytic anemia, iron deficiency anemia, megaloblastic anemia, etc.) and hypoplastic anemia (such as aplastic anemia) ). [0003] Clinically, it is often classified from the pathogenesis and etiology of anemia: [0004] 1. Anemia with reduced erythropoiesis [0005] The abnormality of hematopoietic cells, bone marrow hematopoietic microenvironment and hematopoietic raw materials affect erythropoiesis, which can form erythropoietic anemia. [0006] (1) Anemia caused by abnormal hematopoietic stem and progenitor cells [0007] 1) Aplastic anemia (AA) AA is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56C07J63/00A61P7/06A61P7/00
Inventor 皋林朱延通罗东君吴俊华
Owner 湖北团黄贡茶有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com